A practical reference on 脂肪酸侧链: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
The lungs are especially sensitive and prone to damage, thus to avoid collateral damage to type I and type II pneumocytes, alveolar macrophages are kept in a quiescent state, producing little inflammatory cytokines and displaying little phagocytic activity, as evidenced by downregulated expression of the phagocytic receptor Macrophage 1 antigen (Mac-1). AMs actively suppress the induction of two of the immunity systems of the body: the adaptive immunity and humoral immunity. The adaptive immunity is suppressed through AM's effects on interstitial dendritic cells, B-cells and T-cells, as these cells are less selective of what they destroy, and often cause unnecessary damage to normal cells. To prevent uncontrolled inflammation in the lower respiratory tract, alveolar macrophages secrete nitric oxide, prostaglandins, interleukin-4 and -10(IL-4, IL-10), and transforming growth factor-β (TGF-β).
acetan (Acetobacter xylinum) alginate (Azotobacter vinelandii, Pseudomonas spp.) cellulose (Acetobacter xylinum) chitosan (Mucorales spp.) curdlan (Alcaligenes faecalis var. myxogenes) cyclosophorans (Agrobacterium spp., Rhizobium spp. and Xanthomonas spp.) dextran (Leuconostoc mesenteroides, Leuconostoc dextranicum and Lactobacillus hilgardii) emulsan (Acinetobacter calcoaceticus) galactoglucopolysaccharides (Achromobacter spp., Agrobacterium radiobacter, Pseudomonas marginalis, Rhizobium spp. and Zooglea spp.) galactosaminogalactan (Aspergillus spp.) gellan (Aureomonas elodea and Sphingomonas paucimobilis) glucuronan (Sinorhizobium meliloti) N-acetylglucosamine (Staphylococcus epidermidis) N-acetyl-heparosan (Escherichia coli) hyaluronic acid (Streptococcus equi) indican (Beijerinckia indica) kefiran (Lactobacillus hilgardii) lentinan (Lentinus elodes) levan (Alcaligenes viscosus, Zymomonas mobilis, Bacillus subtilis) pullulan (Aureobasidium pullulans) scleroglucan (Sclerotium rolfsii, Sclerotium delfinii and Sclerotium glucanicum) schizophyllan (Schizophyllum commune) stewartan (Pantoea stewartii subsp. stewartii) succinoglycan (Alcaligenes faecalis var. myxogenes, Sinorhizobium meliloti) xanthan (Xanthomonas campestris) welan (Alcaligenes spp.)
=== Decay by two or more processes === Some quantities decay by two exponential-decay processes simultaneously. In this case, the actual half-life T½ can be related to the half-lives t1 and t2 that the quantity would have if each of the decay processes acted in isolation:
== Clinical significance == Studies on the obestatin/ghrelin ratio in the gastrointestinal tract and plasma are associated with some diseases such as irritable bowel syndrome (IBS), obesity, Prader–Willi syndrome, and type II diabetes mellitus.
Sources: en.wikipedia.org
Through this catabolic process, GSNOR regulates the cellular concentrations of GSNO and plays a central role in regulating the levels of endogenous S-nitrosothiols and controlling protein S-nitrosylation-based signaling.
== tRNA biogenesis == In eukaryotic cells, tRNAs are transcribed by RNA polymerase III as pre-tRNAs in the nucleus. RNA polymerase III recognizes two highly conserved downstream promoter sequences: the 5′ intragenic control region (5′-ICR, D-control region, or A box), and the 3′-ICR (T-control region or B box) inside tRNA genes. The first promoter begins at +8 of mature tRNAs and the second promoter is located 30–60 nucleotides downstream of the first promoter. The transcription terminates after a stretch of four or more thymidines.
=== Books === Two biographies have been written about Staley, both authored by Adriana Rubio—Layne Staley: Angry Chair released in 2003, which contains an alleged final interview of Staley that Rubio claimed to have conducted less than three months before his death, and Layne Staley: Get Born Again, released in 2009, a revised and updated version of her earlier book. Staley's family has disputed Rubio's work, stating they do not believe she interviewed him in 2002. When questioned about the authenticity of the book, Rubio refused to confirm the interview was genuine. Staley's last interview was for the radio program Rockline on July 19, 1999, promoting the release of the compilation album Nothing Safe: Best of the Box with the other members of Alice in Chains. The content of Rubio's book, including what she referred to as Staley's final interview, was called into question in journalist David De Sola's 2015 book Alice in Chains: The Untold Story. De Sola questions not only the content of the interview, which portrays Staley as using his lyrics in casual conversation, it also indicates that Rubio never spoke to him, citing her refusal to release the tape with the interview and the fact that not even her publisher had access to the tape. One of Staley's sisters, Liz Coats, likewise doubted the veracity of the book. Staley was featured on the books Grunge Is Dead: The Oral History of Seattle Rock Music (2009) by Greg Prato, and Everybody Loves Our Town: An Oral History of Grunge (2011) by Mark Yarm.
Sources: en.wikipedia.org
In a 2016 New Internationalist interview, Galloway speculated that an incident of sexual abuse from a colonel, which he suffered when he was 12, caused a "lifelong fear of being gay and this led me into ostentatious, rapacious heterosexual promiscuity". According to Galloway, he grew a moustache at the age of 15, and refused to shave it off when his headmaster objected. He decided, at the age of 18, never to drink alcohol; the reason was originally derived from comments by his father, and he has described alcohol as having a "very deleterious effect on people".
== Description == H. hypnale grows to an average of 30 to 45 cm (12 to 18 in) in total length (including tail). The Armed Forces Pest Management Board states 0.4 to 0.6 m (1 ft 4 in to 2 ft 0 in) in total length. Its build is that of a typical viperid with a stout body and a wide head. The snout is pointed and turned upwards, ending in a hump. The frontal, supraoculars, and parietal shields are large, but those on the snout are small and irregular. The color pattern is grayish with heavy brown mottling, overlaid with a double row of large dark spots. The belly is brownish or yellowish with dark mottling. The tip of the tail is yellow or reddish.
aster In animal cells, a star-shaped system of non-kinetochore microtubules that radiates from a centrosome or from either of the poles of the mitotic spindle during the early stages of cell division.
== Uses == In organic synthesis, HClO converts alkenes to chlorohydrins. In biology, hypochlorous acid is generated in activated neutrophils by myeloperoxidase-mediated peroxidation of chloride ions, and contributes to the destruction of bacteria and other microbes. In medicine, hypochlorous acid water has been used as a disinfectant and sanitiser. In wound care, and as of early 2016, the U.S. Food and Drug Administration has approved products whose main active ingredient is hypochlorous acid for use in treating wounds and various infections in humans and pets. It is also FDA-approved as a preservative for saline solutions. In disinfection, it has been used in the form of liquid spray, wet wipes and aerosolised application. Recent [when?] studies have shown hypochlorous acid water to be suitable for fog and aerosolised application for disinfection chambers and suitable for disinfecting indoor settings, such as offices, hospitals and healthcare clinics. In food service and water distribution, specialized equipment to generate weak solutions of HClO from water and salt is sometimes used to generate adequate quantities of safe (unstable) disinfectant to treat food preparation surfaces and water supplies. It is also commonly used in restaurants due to its non-flammable and nontoxic characteristics. In water treatment, hypochlorous acid is the active sanitizer in hypochlorite-based products (e.g. used in swimming pools).
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
Reversed-phase liquid chromatography with ultraviolet detection is the usual approach, frequently combined with mass spectrometry for identity. Purity is reported as the area percentage of the main peak. Related impurities eluting near the main peak are usually summed and reported separately.